Enlivex Therapeutics Raises $212 Million in Private Placement
Enlivex Therapeutics Ltd. announced a $212 million private placement through the sale of 212 million shares at $1.00 each, an 11.5% premium over the previous closing price. The funds will support a new digital asset treasury strategy and the development of Allocetra™ therapy for knee osteoarthritis. The transaction is expected to close by November 25, 2025, pending customary conditions.
Enlivex Therapeutics Ltd. has announced a private investment in public equity (PIPE) for the sale of 212,000,000 ordinary shares at $1.00 per share, representing an 11.5% premium over the closing price on November 21, 2025. The transaction is expected to raise approximately $212 million in gross proceeds, funded in both US dollars and USDT, before fees and expenses. Enlivex plans to use the net proceeds to implement a new digital asset treasury strategy centered on RAIN prediction markets tokens, while continuing to advance the clinical development of its Allocetra™ therapy for knee osteoarthritis. The closing of the transaction is anticipated on or before November 25, 2025, pending customary closing conditions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enlivex Therapeutics Ltd. published the original content used to generate this news brief on November 24, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
